Eisai (ESAIY) and Biogen (BIIB) announced that Health Canada has issued a Notice of Compliance with Conditions for humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease who are apolipoprotein E 4 non-carriers or heterozygotes and who have confirmed amyloid pathology. LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Strategic Acquisition of Vanqua Bio’s Asset Bolsters Immunology Portfolio, Justifying Buy Rating
- Biogen licenses oral C5aR1 antagonist from Vanqua Bio
- Biogen to present additional results from Phase 3 study of dapirolizumab pegol
- Biogen’s Hold Rating Justified by Limited Growth Prospects and Pipeline Uncertainty
- Biogen price target raised to $153 from $135 at Citi